Protective effect of dexmedetomidine on Tourniquet induced lung injury in patients undergoing total knee arthroplasty: A randomized trial

Objective To investigate whether dexmedetomidine (Dex) can reduce the severity of tourniquet-induced lung injury. Methods 36 patients undergoing total knee arthroplasty with a tourniquet were randomly assigned to control (ischemia/reperfusion [I/R]) group and Dex group. Patients in received loading dose (0.8 μg/kg over 10 min intravenously) followed by continuous infusion (0.5 μg/kg/h until end surgery. The I/R an equal amount 0.9% saline instead Dex. serum concentrations tumor necrosis factor-α (TNF-α), Clara cell protein (CC-16), soluble receptor for advanced glycation products (sRAGE), brain-derived neurotrophic factor (BDNF) measured arterial blood gas analysis was performed before anesthesia 30 min, 6 h, 24 h after release. Results In group, compared baseline, TNF-α, CC-16, sRAGE higher ( p < 0.05) BDNF concentration lower at most time points. than those 0.05), whereas 0.05). analysis, showed significantly partial pressure oxygen arterial/alveolar tension ratio alveolar/arterial difference Conclusion administration partly inhibits release proinflammatory cytokines, affording protection against